ALMS
Alumis Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$11.16
−1.79%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.73
- Revenue estimate
- $1.9M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.11
- EPS estimate
- -$0.77
- Revenue actual
- $1.7M
- Revenue estimate
- $3.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -12.9%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $27
- PT range
- $15 – $37
- Analysts
- 5
4 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026